Table 2 Clinical characteristics and response rate after CHOP-L regimen plus radiation
Characteristics | N (%) | Therapeutic efficacy | P value | |
|---|---|---|---|---|
CR | No CR | Â | ||
Gender | Â | Â | Â | 1.000 |
  Male | 24(63.2%) | 19(79.2%) | 5(20.8%) |  |
  Female | 14(36.8%) | 12(85.7%) | 2(14.3%) |  |
Ann Arbor Stage | Â | Â | Â | 0.026 |
  I | 20(52.6%) | 18(90%) | 2(10%) |  |
  II | 11(28.9%) | 10(90.9%) | 1(9.1%) |  |
  III | 3(7.9%) | 2(66.7%) | 1(33.3%) |  |
  IV | 4(10.5%) | 1(25%) | 3(75%) |  |
Tumor extending to adjacent organ/tissue in UNKTL | Â | Â | Â | 0.157 |
  Yes | 26(72.2%) | 20(76.9%) | 6(23.1%) |  |
  No | 10(27.8%) | 10(100%) | 0(0%) |  |
Region LN involvement | Â | Â | Â | 0.222 |
  Yes | 18(47.4%) | 13(72.2%) | 5(27.8%) |  |
  No | 20(52.6%) | 18(90%) | 2(10%) |  |
Bony invasion or perforation | Â | Â | Â | 1.000 |
  Yes | 4(10.5%) | 3(75%) | 1(25%) |  |
  No | 34(89.5%) | 28(82.4%) | 6(17.6%) |  |
B symptoms | Â | Â | Â | 0.014 |
  Yes | 22(57.9%) | 15(68.2%) | 7(31.8%) |  |
  No | 16(42.1%) | 16(100%) | 0(0%) |  |
ECOG performance status | Â | Â | Â | 0.013 |
  0 | 13(34.2%) | 13(100%) | 0(0%) |  |
  1 | 24(63.2%) | 18(75%) | 6(25%) |  |
  2 | 1(2.6%) | 0(0%) | 1(100%) |  |
IPI score | Â | Â | Â | 0.001 |
  0~1 | 27(71.1%) | 26(96.3%) | 1(3.7%) |  |
  2 | 7(18.4%) | 3(42.9%) | 4(57.1%) |  |
  3 | 2(5.3%) | 1(50%) | 1(50%) |  |
  4~5 | 2(5.3%) | 1(50%) | 1(50%) |  |
NK/T-cell PI score | Â | Â | Â | 0.001 |
  0 | 10(26.3%) | 10(100%) | 0(0%) |  |
  1 | 13(34.2%) | 12(92.3%) | 1(7.7%) |  |
  2 | 7(18.4%) | 6(85.7%) | 1(14.3%) |  |
  3~4 | 8(21.1%) | 3(37.5%) | 5(62.5%) |  |
Serum LDH level | Â | Â | Â | 0.013 |
  Elevated | 7(18.4%) | 3(42.9%) | 4(57.1%) |  |
  Normal | 31(81.6%) | 28(90.3%) | 3(9.7%) |  |
ESR | Â | Â | Â | 0.650 |
  >30 mm/hr | 10(26.3%) | 9(90%) | 1(10%) |  |
  ≤30 mm/hr | 28(73.7%) | 22(78.6%) | 6(21.4%) |  |
β2- microglobulin |  |  |  | 1.000 |
  Elevated | 5(13.2%) | 4(80%) | 1(20%) |  |
  Normal | 33(86.8%) | 27(81.8%) | 6(18.2%) |  |
Hemoglobin | Â | Â | Â | 0.339 |
  <110 g/L | 2(5.3%) | 1(50%) | 1(50%) |  |
  ≥110 g/L | 36(94.7%) | 30(83.3%) | 6(16.7%) |  |
White blood cell count | Â | Â | Â | 0.004 |
  <4.0 × 109/L | 9(23.7%) | 4(44.4%) | 5(55.6%) |  |
  ≥4.0 × 109/L | 29(76.3%) | 27(93.1%) | 2(6.9%) |  |
Pegaspargase replacement of L-asparaginase | Â | Â | Â | 1.000 |
  yes | 11(28.9%) | 9(81.8%) | 2(18.2%) |  |
  no | 27(71.1%) | 22(81.5%) | 5(18.5%) |  |